


LIST OF FIGURES



No.

Title

Prologue

- 1 Multistep process of cancer development
- 2 The protein production pathway
- 3 Major components of cell membrane glycoproteins
- 4 Important role of MMPs in cancer

Introduction

- 1 Cancer: a disease of the tissue microenvironment
- 2 B cell development and multiple myeloma
- 3 Production of the M-protein in multiple myeloma
- 4 Anatomical view of cervical cancer
- 5 HPV and cervical cancer progression
- 6 Basic experimental views of expression proteomics in cancer
- 7 Pathway of protein post-translation modifications from DNA
- 8 Domain structure of MMPs
- 9 Schematic representation of TIMP-1 structure
- 10 The steps of metastatic cascade

Materials and Methods

- 1 Schematic diagram shows the correlation between antigen and antibody by the precipitation reaction
- 2 Schematic diagram of PAGE
- 3 Schematic diagram of protein linearized in presence of SDS
- 4 Semidry method
- 5 Schematic diagram of 2D-gel electrophoresis
- 6 Schematic diagram of gelatin zymography protocol
- 7 Schematic diagram showing principle of ELISA
- 8 Schematic diagram of ELISA protocol

Results

- 1 Representative patterns of agarose gel electrophoresis in controls and MM patients
- 2 Comparison of serum total protein fractions by agarose gel electrophoresis between controls and MM patients
- 3 ROC curve for serum total protein fractions between controls and MM patients
- 4 Comparison of serum total protein fractions by agarose gel electrophoresis between group-I and group-II MM patients
- 5 ROC curve for serum total protein fractions in group-I and group-II MM patients
- 6 Representative diagram of immunoprofiling in controls and MM patients
- 7 Comparison of serum immunoglobulin levels between controls and MM patients
- 8 Representative patterns of serum total protein profiles by native-PAGE in controls and MM patients
- 9 Comparison of serum native-PAGE profiles between controls and MM

- patients
- 10 ROC curve for serum protein profiles in controls and MM patients
 - 11 Comparison of the serum native-PAGE profiles between group-I and group-II MM patients
 - 12 ROC curve for serum protein profiles in group-I and group-II MM patients
 - 13 Comparison of serum native-PAGE profiles ratio between controls and MM patients
 - 14 Comparison of serum protein profiles ratio between controls and MM patients
 - 15 Comparison of serum native-PAGE profiles ratio between group-I and group-II MM patients
 - 16 ROC curve for comparison between group-I and group-II MM patients
 - 17 Comparison of serum levels of glycoconjugates and protein ratio of glycoconjugates between controls and MM patients
 - 18 ROC curve for comparison between controls and MM patients
 - 19 Comparison of serum levels of glycoconjugates and protein ratio of glycoconjugates between group-I and group-II MM patients
 - 20 ROC curve for comparison between group-I and group-II MM patients
 - 21 Representative glycoproteins native-PAGE electrophoretic patterns in controls and MM patients
 - 22 Comparison of the serum glycoprotein profiles (native-PAGE) between controls and MM patients
 - 23 ROC curve for comparison of glycoprotein profiles between controls and MM patients
 - 24 Comparison of the serum glycoprotein profiles (native-PAGE) between group-I and group-II MM patients
 - 25 ROC curve for comparison in glycoprotein profiles between group-I and group-II MM patients
 - 26 Comparison of ratio of serum glycoprotein fractions between controls and MM patients
 - 27 ROC curve for comparison between controls and MM patients
 - 28 Comparison of serum glycoprotein ratio between group-I and group-II MM patients
 - 29 ROC curve for comparison of glycoprotein profiles between group-I and group-II MM patients
 - 30 Representative zymograms of MMP-2(a) and MMP-9(b) latent and active standards
 - 31 Standard graphs for MMP-2 (a; latent, b; active) and MMP-9 (c; latent, d; active)
 - 32 Representative zymograms of MMP-2 and MMP-9 in controls and MM patients
 - 33 Comparison of serum proMMP-2, activeMMP-2, totalMMP-2 and activation ratio of MMP-2 by zymography between controls and MM patients
 - 34 Comparison of serum proMMP-9, activeMMP-9, totalMMP-9 and activation ratio of MMP-9 by zymography between controls and MM

- patients
- 35 ROC curve for comparison between controls and MM patients
 - 36 Comparison of serum proMMP-2, activeMMP-2, totalMMP-2 and activation ratio of MMP-2 by zymography between group-I and group-II MM patients
 - 37 Comparison of serum proMMP-9, activeMMP-9, totalMMP-9 and activation of ratio MMP-9 by zymography between group-I and group-II MM patients
 - 38 Standard curves for total MMP-2, total MMP-9 and TIMP-1, TIMP-2 by ELISA
 - 39 Comparison of serum levels of the total MMP-2, total MMP-9, TIMP-1 and TIMP-2 by ELISA between controls and MM patients
 - 40 Comparison of serum total MMP-2, total MMP-9, TIMP-1 and TIMP-2 between controls and MM patients
 - 41 Comparison of serum levels of the total MMP-2, total MMP-9, TIMP-1 and TIMP-2 by ELISA between group-I and group-II MM patients
 - 42 Representative patterns of serum total protein profiling by SDS-PAGE in controls and MM patients
 - 43 SDS-PAGE patterns of protein molecular weight marker and isolated M-Protein in MM patients
 - 44 Representative graphs of standard protein and calculated protein molecular weight marker
 - 45 Representative patterns of isolated M-Protein by 2D-PAGE
 - 46 Levels of glycoconjugates in isolated M-protein
 - 47 Representative native-PAGE patterns in controls and cervical cancer patients
 - 48 Comparison of the serum native-PAGE profiles by between controls and cervical cancer patients
 - 49 ROC curve for comparison between controls and cervical cancer patients
 - 50 Comparison of serum total protein profiles ratio by native-PAGE between controls and cervical cancer patients
 - 51 ROC curve for comparison between controls and cervical cancer patients
 - 52 Representative patterns of serum protein profiles by SDS-PAGE in controls and cervical cancer patients
 - 53 Comparison of serum glycoconjugates and protein ratio of glycoconjugates between controls and cervical cancer patients
 - 54 ROC curve for comparison between controls and cervical cancer patients
 - 55 Representative patterns of glycoproteins by native-PAGE in controls and cervical cancer patients
 - 56 Comparison of glycoprotein native-PAGE profiles between controls and cervical cancer patients
 - 57 ROC curve for comparison of glycoprotein profiles between controls and cervical cancer patients
 - 58 Comparison of glycoprotein profiles ratio by native-PAGE between controls and cervical cancer patients

- 59 ROC curve for comparison of native-PAGE glycoprotein profiles between controls and cervical cancer patients
- 60 Representative zymograms of MMP-2 and MMP-9 in controls and cervical cancer patients
- 61 Comparison of serum proMMP-2, activeMMP-2, totalMMP-2 and activation ratio of MMP-2 by zymography between controls and cervical cancer patients
- 62 Comparison of serum proMMP-9, activeMMP-9, totalMMP-9 and activation ratio of MMP-9 by zymography between controls and cervical cancer patients
- 63 ROC curve for comparison between controls and cervical cancer patients
- 64 Percentage activity of active forms of MMP-2 and MMP-9 in cervical cancer patients
- 65 Comparison of serum levels of the total MMP-2, total MMP-9, TIMP-1 and TIMP-2 by ELISA between controls and cervical cancer patients
- 66 Comparison of serum levels of the total MMP-2, total MMP-9, TIMP-1 and TIMP-2 by ELISA between controls and cervical cancer patients